Comparison and evaluation of two C-reactive protein assays based on particle-enhanced immunoturbidimetry

Journal of Clinical Laboratory Analysis

Volumn 21, Issue 2, 2007, Pages 71-76

  Şişman, Ali Riza ^a   Küme, Tuncay ^a   Taş, Gültekin ^b   Akan, Pinar ^a   Tuncel, Pinar ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b KENT HOSPITAL   (Turkey)

Author keywords

Analytical performance characteristics; C reactive protein; High sensitivity C reactive protein; Method comparison; Method validation

Indexed keywords

C REACTIVE PROTEIN;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DEVICE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PROTEIN DETERMINATION; REGRESSION ANALYSIS; TURBIDIMETRY;

C-REACTIVE PROTEIN; CLINICAL LABORATORY TECHNIQUES; HUMANS; IMMUNOASSAY; NEPHELOMETRY AND TURBIDIMETRY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

TINA;

EID: 34047237873     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20141     Document Type: Article

References (22)

1. Pepys MB. C-reactive protein fifty years on. Lancet 1981;1: 653-657.
2. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001;47: 426-430.
3. Frohlich M, Sund M, Thorand B, Hutchinson WL, Pepys MB, Koenig W. Lack of seasonal variation in C-reactive protein. Clin Chem 2002;48:575-577.
4. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med 1999;6:1019-1025.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
6. Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005;2:29-36.
7. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-844.
8. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003;107:391-397.
9. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105: 2595-2599.
10. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285: 2481-2485.
11. Tice JA, Browner W, Tracy RP, Cummings SR. The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women. Am J Med 2003;114:199-205.
12. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and prevention and the American Heart Association. Circulation 2003;107: 499-511.
13. Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 2003;107: 370-371.
14. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Clin Chem 2000;46:461-468.
15. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45: 2136-2141.
16. National Committee for Clinical Laboratory Standards. "Method comparison and bias estimation using patient samples. Approved guideline." NCCLS document EP9-A. Villanova, PA: NCCLS Publications; 2002.
17. Martin RF. General deming regression for estimating systematic bias and its confidence interval in method-comparison studies. Clin Chem 2000;46:100-104.
18. Bland JM, Altman DG. Comparing methods of measurements: why plotting difference against standard method is misleading. Lancet 1995;346:1085-1087.
19. Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem. 2001;47:418-425.
20. Ledue T, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: Implications for cardiovascular disease risk assessment. Clin Chem 2003;49:1258-1271.
21. Rifai N, Warnick GR. Quality specifications and the assessment of the biochemical risk of atherosclerosis. Clin Chim Acta 2004;346:55-64.
22. Kimberly MM, Vesper HW, Caudill SP, et al. Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Phase I: evaluation of secondary reference materials. Clin Chem 2003;49:611-616.